Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
L3Harris
LHX
|
$148M |
| 2 |
GE HealthCare
GEHC
|
$118M |
| 3 |
Atlassian
TEAM
|
$101M |
| 4 |
Monster Beverage
MNST
|
$81.1M |
| 5 |
PACCAR
PCAR
|
$48.1M |
Top Sells
| 1 |
Apple
AAPL
|
$360M |
| 2 |
Microsoft
MSFT
|
$199M |
| 3 |
NVIDIA
NVDA
|
$99.2M |
| 4 |
Amazon
AMZN
|
$85.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$83.8M |
Sector Composition
| 1 | Technology | 28.64% |
| 2 | Healthcare | 14.81% |
| 3 | Consumer Discretionary | 11.76% |
| 4 | Industrials | 9.45% |
| 5 | Communication Services | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2576
BrightView Holdings
BV
$1.37B
| $395K | ﹤0.01% | 70,300 -6,900 | -9% | -$38.8K |
|
|
ENFN
2577
DELISTED
Enfusion, Inc.
ENFN
| $392K | ﹤0.01% | 37,300 -3,100 | -8% | -$32.6K |
|
2578
Purple Innovation
PRPL
$126M
| $388K | ﹤0.01% | 147,000 +17,100 | +13% | +$45.1K |
|
2579
Heron Therapeutics
HRTX
$207M
| $387K | ﹤0.01% | 256,600 +8,800 | +4% | +$13.3K |
|
|
CMAX
2580
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $383K | ﹤0.01% | 143,600 +30,400 | +27% | +$81.2K |
|
2581
Arhaus
ARHS
$1.65B
| $379K | ﹤0.01% | +45,700 | New | +$379K |
|
|
JBIO
2582
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $375K | ﹤0.01% | 18,601 -2,100 | -10% | -$42.4K |
|
|
OGI
2583
Organigram Holdings
OGI
$232M
| $369K | ﹤0.01% | 581,000 -66,000 | -10% | -$41.9K |
|
|
ALLK
2584
DELISTED
Allakos
ALLK
| $368K | ﹤0.01% | 82,700 -70,800 | -46% | -$315K |
|
2585
Angi Inc
ANGI
$786M
| $363K | ﹤0.01% | 160,100 -10,300 | -6% | -$23.4K |
|
|
CLCO
2586
Cool Company
CLCO
$428M
| $356K | ﹤0.01% | +29,245 | New | +$356K |
|
2587
NuScale Power
SMR
$4.64B
| $355K | ﹤0.01% | 39,100 -1,900 | -5% | -$17.3K |
|
2588
HilleVax
HLVX
$105M
| $350K | ﹤0.01% | 21,200 -7,000 | -25% | -$116K |
|
2589
Kezar Life Sciences
KZR
$28.9M
| $346K | ﹤0.01% | 110,700 -13,200 | -11% | -$41.3K |
|
2590
Precigen
PGEN
$1.34B
| $345K | ﹤0.01% | 325,000 +81,300 | +33% | +$86.2K |
|
2591
Entrada Therapeutics
TRDA
$208M
| $344K | ﹤0.01% | 23,700 -2,800 | -11% | -$40.6K |
|
2592
Bristow Group
VTOL
$1.11B
| $340K | ﹤0.01% | 15,200 -1,500 | -9% | -$33.6K |
|
2593
CS Disco
LAW
$338M
| $338K | ﹤0.01% | 50,900 +16,600 | +48% | +$110K |
|
|
CANO
2594
DELISTED
Cano Health, Inc.
CANO
| $336K | ﹤0.01% | 369,500 -22,500 | -6% | -$20.5K |
|
2595
Microvast
MVST
$864M
| $331K | ﹤0.01% | 267,100 -25,100 | -9% | -$31.1K |
|
2596
Janux Therapeutics
JANX
$1.37B
| $327K | ﹤0.01% | +27,000 | New | +$327K |
|
2597
Monte Rosa Therapeutics
GLUE
$296M
| $326K | ﹤0.01% | 41,800 -2,100 | -5% | -$16.4K |
|
2598
Paymentus
PAY
$4.88B
| $320K | ﹤0.01% | 36,100 -3,500 | -9% | -$31K |
|
2599
Energy Vault
NRGV
$327M
| $319K | ﹤0.01% | 149,186 -16,300 | -10% | -$34.9K |
|
2600
Seer Inc
SEER
$115M
| $318K | ﹤0.01% | 82,300 -7,700 | -9% | -$29.7K |
|